関連する実験動画

Updated: Jul 5, 2026

A High Throughput, Multiplexed and Targeted Proteomic CSF Assay to Quantify Neurodegenerative Biomarkers and Apolipoprotein E Isoforms Status
07:08

A High Throughput, Multiplexed and Targeted Proteomic CSF Assay to Quantify Neurodegenerative Biomarkers and Apolipoprotein E Isoforms Status

Published on: October 20, 2016

8.4K

血漿由来タウ：初の市販イムノアッセイの分析および臨床的検証

Michel N Nafash1,2,3, Sarah E Svirsky4, Xuemei Zeng1,2,3

  • 1Department of Psychiatry, School of Medicine, University of Pittsburgh, Pittsburgh, PA, USA.

Scientific reports
|February 21, 2026
PubMed
まとめ

No abstract available in PubMed .

キーワード:
アルツハイマー病分析的検証血液ベースのバイオマーカー脳由来タウ臨床的検証外傷性脳損傷

さらに関連する動画

In Vitro Assay for Studying the Aggregation of Tau Protein and Drug Screening09:49

In Vitro Assay for Studying the Aggregation of Tau Protein and Drug Screening

Published on: November 20, 2018

19.8K
Cell-based Assay to Study Antibody-mediated Tau Clearance by Microglia07:18

Cell-based Assay to Study Antibody-mediated Tau Clearance by Microglia

Published on: November 9, 2018

9.0K

関連する概念動画

Enzyme-Linked Immunosorbent Assay01:33

Enzyme-Linked Immunosorbent Assay

In 1971, Peter Perlman and Eva Engvall developed an Enzyme-linked immunosorbent assay (ELISA or EIA). ELISA differs from western blot in that the assays are conducted in microtiter plates or in vivo rather than on an absorbent membrane.
There are many different types of ELISAs, but they all involve an antibody molecule whose constant region binds an enzyme, leaving the variable region free to bind its specific antigen.  Enzyme-substrate reaction allows the antigen to be visualized or quantified.